Trial Profile
A retrospective study of nilotinib in patients with imatinib resistant chronic myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2015
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 09 Oct 2015 New trial record
- 23 Sep 2015 Results published in the Clinical Therapeutics.